Condition: Duchenne Muscular Dystrophy · Exon 44 · DMD · Sponsor: NS Pharma, Inc.
This is a Phase 2, open-label, multi-center, 2-part study of NS-089/NCNP-02 administered by weekly IV infusion to ambulant boys aged ≥4 to \<15 years with DMD due to mutations amenable to exon 44 skipping. Participants will receive a selected dose of NS-089/NCNP-02 administered once weekly. The study consists of 2 parts: Part 1 and Part 2. Six participants (Cohort 1) will participate in both Part 1 and Part 2, and 14 participants (Cohort 2) will be added for Part 2.
This description comes directly from the study's public registry record.
Trial info · 1-866-677-6276 · trialinfo@nspharma.com
Always discuss trial participation with your own doctor first.
| Children's Hospital Colorado | Aurora, Colorado, United States | Recruiting |
| Rare Disease Research, LLC - FL | Kissimmee, Florida, United States | Recruiting |
| Rare Disease Research | Atlanta, Georgia, United States | Recruiting |
| Ann and Robert H. Lurie Children's Hospital of Chicago | Chicago, Illinois, United States | Recruiting |
| University of Kansas Medical Center (KUMC) | Kansas City, Kansas, United States | Recruiting |
| Cincinnati Children's Hospital Medical Center | Cincinnati, Ohio, United States | Recruiting |
| The Children's Hospital of Philadelphia (CHOP) | Philadelphia, Pennsylvania, United States | Recruiting |
| University of Pittsburgh School of Medicine | Pittsburgh, Pennsylvania, United States | Recruiting |
| UT Southwestern/Children's Health | Dallas, Texas, United States | Recruiting |
| Virginia Commonwealth University Health System | Richmond, Virginia, United States | Recruiting |
| Perth Children's Hospital | Nedlands, Western Australia, Australia | Not Yet Recruiting |
| Alberta Children's Hospital | Calgary, Alberta, Canada | Not Yet Recruiting |
+ 13 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05996003